[Pj-015] Japanese Poster Session 015「Neuroimmunology: NMOSD and MOGAD 1」

[Pj-015-2] Survey on Use of Inebilizumab for NMOSD (Third interim analysis): Use of Steroids

Shinya Hirota¹, Kyoko Kato¹, Yoshikazu Naito¹, Yoshito Nagano², Hideaki Hida¹, Saori Yamauchi¹, Muneyoshi Kudo¹, Satoshi Yuki¹, Kazuo Fujihara^3,4 (1.Mitsubishi Tanabe Pharma Corporation, Japan, 2.Shion Daini Clinic, Japan, 3.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Japan, 4.Southern TOHOKU Research Institute for Neuroscience, Japan)